{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:25:03Z","timestamp":1792790703606,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100019063","name":"Tandem Diabetes Care","doi-asserted-by":"publisher","award":["Research grant"],"award-info":[{"award-number":["Research grant"]}],"id":[{"id":"10.13039\/100019063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015769","name":"Dexcom","doi-asserted-by":"publisher","award":["Research grant"],"award-info":[{"award-number":["Research grant"]}],"id":[{"id":"10.13039\/100015769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00125-025-06366-x","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T17:03:06Z","timestamp":1739293386000},"page":"948-960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6007-6715","authenticated-orcid":false,"given":"Jolien","family":"De Meulemeester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Keymeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"De Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Van Huffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youri","family":"Taes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Ballaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Spincemaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lapauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Vanhaverbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ine","family":"Lowyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Vercammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ides M.","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Preumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2100-4927","authenticated-orcid":false,"given":"Sara","family":"Charleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Fieuws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4055-5233","authenticated-orcid":false,"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9111-4561","authenticated-orcid":false,"given":"Pieter","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"6366_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/s2213-8587(17)30167-5","volume":"5","author":"A Weisman","year":"2017","unstructured":"Weisman A, Bai JW, Cardinez M et al (2017) Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol 5:501\u2013512. https:\/\/doi.org\/10.1016\/s2213-8587(17)30167-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6366_CR2","doi-asserted-by":"publisher","first-page":"k1310","DOI":"10.1136\/bmj.k1310","volume":"361","author":"E Bekiari","year":"2018","unstructured":"Bekiari E, Kitsios K, Thabit H et al (2018) Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ 361:k1310. https:\/\/doi.org\/10.1136\/bmj.k1310","journal-title":"BMJ"},{"key":"6366_CR3","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/s0140-6736(18)31947-0","volume":"392","author":"M Tauschmann","year":"2018","unstructured":"Tauschmann M, Thabit H, Bally L et al (2018) Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet 392:1321\u20131329. https:\/\/doi.org\/10.1016\/s0140-6736(18)31947-0","journal-title":"Lancet"},{"key":"6366_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/s0140-6736(20)32514-9","volume":"397","author":"RM Bergenstal","year":"2021","unstructured":"Bergenstal RM, Nimri R, Beck RW et al (2021) A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 397:208\u2013219. https:\/\/doi.org\/10.1016\/s0140-6736(20)32514-9","journal-title":"Lancet"},{"key":"6366_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2337\/dc20-2250","volume":"44","author":"OJ Collyns","year":"2021","unstructured":"Collyns OJ, Meier RA, Betts ZL et al (2021) Improved glycemic outcomes with medtronic MiniMed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care 44:969\u2013975. https:\/\/doi.org\/10.2337\/dc20-2250","journal-title":"Diabetes Care"},{"key":"6366_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1089\/dia.2022.0558","volume":"25","author":"RW Beck","year":"2023","unstructured":"Beck RW, Kanapka LG, Breton MD et al (2023) A meta-analysis of randomized trial outcomes for the t:slim X2 insulin pump with control-IQ technology in youth and adults from age 2 to 72. Diabetes Technol Ther 25:329\u2013342. https:\/\/doi.org\/10.1089\/dia.2022.0558","journal-title":"Diabetes Technol Ther"},{"key":"6366_CR7","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/s2666-7568(22)00005-8","volume":"3","author":"CK Boughton","year":"2022","unstructured":"Boughton CK, Hartnell S, Thabit H et al (2022) Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. Lancet Heal Longev 3:e135\u2013e142. https:\/\/doi.org\/10.1016\/s2666-7568(22)00005-8","journal-title":"Lancet Heal Longev"},{"key":"6366_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa2111673","volume":"386","author":"J Ware","year":"2022","unstructured":"Ware J, Allen JM, Boughton CK et al (2022) Randomized trial of closed-loop control in very young children with type 1 diabetes. N Engl J Med 386:209\u2013219. https:\/\/doi.org\/10.1056\/NEJMoa2111673","journal-title":"N Engl J Med"},{"key":"6366_CR9","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/s2589-7500(19)30003-2","volume":"1","author":"PY Benhamou","year":"2019","unstructured":"Benhamou PY, Franc S, Reznik Y et al (2019) Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digit Heal 1:e17\u2013e25. https:\/\/doi.org\/10.1016\/s2589-7500(19)30003-2","journal-title":"Lancet Digit Heal"},{"key":"6366_CR10","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/s2213-8587(22)00212-1","volume":"10","author":"P Choudhary","year":"2022","unstructured":"Choudhary P, Kolassa R, Keuthage W et al (2022) Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol 10:720\u2013731. https:\/\/doi.org\/10.1016\/s2213-8587(22)00212-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6366_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1056\/NEJMoa2203913","volume":"387","author":"MJ Burnside","year":"2022","unstructured":"Burnside MJ, Lewis DM, Crocket HR et al (2022) Open-source automated insulin delivery in type 1 diabetes. N Engl J Med 387:869\u2013881. https:\/\/doi.org\/10.1056\/NEJMoa2203913","journal-title":"N Engl J Med"},{"key":"6366_CR12","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1007\/s00125-024-06165-w","volume":"67","author":"CK Boughton","year":"2024","unstructured":"Boughton CK, Hovorka R (2024) The role of automated insulin delivery technology in diabetes. Diabetologia 67:2034\u20132044. https:\/\/doi.org\/10.1007\/s00125-024-06165-w","journal-title":"Diabetologia"},{"key":"6366_CR13","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.2337\/dc18-1249","volume":"41","author":"S Brown","year":"2018","unstructured":"Brown S, Raghinaru D, Emory E, Kovatchev B (2018) First look at control-IQ: a new-generation automated insulin delivery system. Diabetes Care 41:2634\u20132636. https:\/\/doi.org\/10.2337\/dc18-1249","journal-title":"Diabetes Care"},{"key":"6366_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1089\/dia.2021.0089","volume":"23","author":"YC Kudva","year":"2021","unstructured":"Kudva YC, Laffel LM, Brown SA et al (2021) Patient-reported outcomes in a randomized trial of closed-loop control: the pivotal international diabetes closed-loop trial. Diabetes Technol Ther 23:673\u2013683. https:\/\/doi.org\/10.1089\/dia.2021.0089","journal-title":"Diabetes Technol Ther"},{"key":"6366_CR15","doi-asserted-by":"publisher","first-page":"111114","DOI":"10.1016\/j.diabres.2024.111114","volume":"208","author":"KK Hood","year":"2024","unstructured":"Hood KK, Schneider-Utaka AK, Reed ZW et al (2024) Patient reported outcomes (PROs) and user experiences of young children with type 1 diabetes using t:slim X2 insulin pump with control-IQ technology. Diabetes Res Clin Pract 208:111114. https:\/\/doi.org\/10.1016\/j.diabres.2024.111114","journal-title":"Diabetes Res Clin Pract"},{"key":"6366_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s13300-023-01394-5","volume":"14","author":"S Peacock","year":"2023","unstructured":"Peacock S, Frizelle I, Hussain S (2023) A systematic review of commercial hybrid closed-loop automated insulin delivery systems. Diabetes Ther 14:839\u2013855. https:\/\/doi.org\/10.1007\/s13300-023-01394-5","journal-title":"Diabetes Ther"},{"key":"6366_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/dia.2023.0442","volume":"26","author":"EG Considine","year":"2024","unstructured":"Considine EG, Sherr JL (2024) Real-world evidence of automated insulin delivery system use. Diabetes Technol Ther 26:53\u201365. https:\/\/doi.org\/10.1089\/dia.2023.0442","journal-title":"Diabetes Technol Ther"},{"key":"6366_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/s2213-8587(22)00319-9","volume":"11","author":"T Battelino","year":"2023","unstructured":"Battelino T, Alexander CM, Amiel SA et al (2023) Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol 11:42\u201357. https:\/\/doi.org\/10.1016\/s2213-8587(22)00319-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6366_CR19","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Lawrence Erlbaum Associates, Hillsdale, NJ","edition":"2"},{"key":"6366_CR20","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","volume":"381","author":"SA Brown","year":"2019","unstructured":"Brown SA, Kovatchev BP, Raghinaru D et al (2019) Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 381:1707\u20131717. https:\/\/doi.org\/10.1056\/NEJMoa1907863","journal-title":"N Engl J Med"},{"key":"6366_CR21","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa2004736","volume":"383","author":"MD Breton","year":"2020","unstructured":"Breton MD, Kanapka LG, Beck RW et al (2020) A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med 383:836\u2013845. https:\/\/doi.org\/10.1056\/NEJMoa2004736","journal-title":"N Engl J Med"},{"key":"6366_CR22","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1111\/dom.15766","volume":"26","author":"A Rizzi","year":"2024","unstructured":"Rizzi A, Tartaglione L, Lucaccini Paoli L et al (2024) Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: a 1-year real-world assessment. Diabetes Obes Metab 26:4078\u20134086. https:\/\/doi.org\/10.1111\/dom.15766","journal-title":"Diabetes Obes Metab"},{"key":"6366_CR23","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00125-024-06171-y","volume":"67","author":"J De Meulemeester","year":"2024","unstructured":"De Meulemeester J, Charleer S, Visser MM et al (2024) The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study. Diabetologia 67:1527\u20131535. https:\/\/doi.org\/10.1007\/s00125-024-06171-y","journal-title":"Diabetologia"},{"key":"6366_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1089\/dia.2020.0388","volume":"23","author":"JE Pinsker","year":"2021","unstructured":"Pinsker JE, M\u00fcller L, Constantin A et al (2021) Real-world patient-reported outcomes and glycemic results with initiation of control-IQ technology. Diabetes Technol Ther 23:120\u2013127. https:\/\/doi.org\/10.1089\/dia.2020.0388","journal-title":"Diabetes Technol Ther"},{"key":"6366_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1089\/dia.2023.0341","volume":"26","author":"R Graham","year":"2024","unstructured":"Graham R, Mueller L, Manning M et al (2024) Real-world use of control-IQ technology is associated with a lower rate of severe hypoglycemia and diabetic ketoacidosis than historical data: results of the control-IQ observational (CLIO) prospective study. Diabetes Technol Ther 26:24\u201332. https:\/\/doi.org\/10.1089\/dia.2023.0341","journal-title":"Diabetes Technol Ther"},{"key":"6366_CR26","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1089\/dia.2020.0593","volume":"23","author":"MA Burckhardt","year":"2021","unstructured":"Burckhardt MA, Abraham MB, Dart J et al (2021) Impact of hybrid closed loop therapy on hypoglycemia awareness in individuals with type 1 diabetes and impaired hypoglycemia awareness. Diabetes Technol Ther 23:482\u2013490. https:\/\/doi.org\/10.1089\/dia.2020.0593","journal-title":"Diabetes Technol Ther"},{"key":"6366_CR27","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.2337\/dc23-0685","volume":"46","author":"E Renard","year":"2023","unstructured":"Renard E, Joubert M, Villard O et al (2023) Safety and efficacy of sustained automated insulin delivery compared with sensor and pump therapy in adults with type 1 diabetes at high risk for hypoglycemia: a randomized controlled trial. Diabetes Care 46:2180\u20132187. https:\/\/doi.org\/10.2337\/dc23-0685","journal-title":"Diabetes Care"},{"key":"6366_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1089\/dia.2022.0506","volume":"25","author":"AJ Flatt","year":"2023","unstructured":"Flatt AJ, Peleckis AJ, Dalton-Bakes C et al (2023) Automated insulin delivery for hypoglycemia avoidance and glucose counterregulation in long-standing type 1 diabetes with hypoglycemia unawareness. Diabetes Technol Ther 25:302\u2013314. https:\/\/doi.org\/10.1089\/dia.2022.0506","journal-title":"Diabetes Technol Ther"},{"key":"6366_CR29","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1177\/19322968231182406","volume":"18","author":"SK Malone","year":"2023","unstructured":"Malone SK, Matus AM, Flatt AJ et al (2023) Prolonged use of an automated insulin delivery system improves sleep in long-standing type 1 diabetes complicated by impaired awareness of hypoglycemia. J Diabetes Sci Technol 18:1416\u20131423. https:\/\/doi.org\/10.1177\/19322968231182406","journal-title":"J Diabetes Sci Technol"},{"key":"6366_CR30","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1001\/jama.2013.278576","volume":"310","author":"P Choudhary","year":"2013","unstructured":"Choudhary P (2013) Insulin pump therapy with automated insulin suspension: toward freedom from nocturnal hypoglycemia. JAMA 310:1235\u20131236. https:\/\/doi.org\/10.1001\/jama.2013.278576","journal-title":"JAMA"},{"key":"6366_CR31","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(18)30297-6","volume":"391","author":"L Heinemann","year":"2018","unstructured":"Heinemann L, Freckmann G, Ehrmann D et al (2018) Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet 391:1367\u20131377. https:\/\/doi.org\/10.1016\/S0140-6736(18)30297-6","journal-title":"Lancet"},{"key":"6366_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2337\/diacare.18.4.517","volume":"18","author":"WL Clarke","year":"1995","unstructured":"Clarke WL, Cox DJ, Gonder-Frederick LA et al (1995) Reduced awareness of hypoglycemia in adults with IDDM: a prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 18:517\u2013522. https:\/\/doi.org\/10.2337\/diacare.18.4.517","journal-title":"Diabetes Care"},{"key":"6366_CR33","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2337\/dc23-0635","volume":"46","author":"TSJ Crabtree","year":"2023","unstructured":"Crabtree TSJ, Griffin TP, Yap YW et al (2023) Hybrid closed-loop therapy in adults with type 1 diabetes and above-target HbA1c: a real-world observational study. Diabetes Care 46:1831\u20131838. https:\/\/doi.org\/10.2337\/dc23-0635","journal-title":"Diabetes Care"},{"key":"6366_CR34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1089\/dia.2021.0165","volume":"23","author":"LH Messer","year":"2021","unstructured":"Messer LH, Berget C, Pyle L et al (2021) Real-world use of a new hybrid closed loop improves glycemic control in youth with type 1 diabetes. Diabetes Technol Ther 23:837\u2013843. https:\/\/doi.org\/10.1089\/dia.2021.0165","journal-title":"Diabetes Technol Ther"},{"key":"6366_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2337\/dc23-1355","volume":"47","author":"PI Beato-V\u00edbora","year":"2024","unstructured":"Beato-V\u00edbora PI, Chico A, Moreno-Fernandez J et al (2024) A multicenter prospective evaluation of the benefits of two advanced hybrid closed-loop systems in glucose control and patient-reported outcomes in a real-world setting. Diabetes Care 47:216\u2013224. https:\/\/doi.org\/10.2337\/dc23-1355","journal-title":"Diabetes Care"},{"key":"6366_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11892-017-0965-1","volume":"17","author":"U Pedersen-Bjergaard","year":"2017","unstructured":"Pedersen-Bjergaard U, Thorsteinsson B (2017) Reporting severe hypoglycemia in type 1 diabetes: facts and pitfalls. Curr Diab Rep 17:131. https:\/\/doi.org\/10.1007\/s11892-017-0965-1","journal-title":"Curr Diab Rep"},{"key":"6366_CR37","doi-asserted-by":"publisher","first-page":"e14745","DOI":"10.1111\/dme.14745","volume":"39","author":"HL Stuckey","year":"2022","unstructured":"Stuckey HL, Desai U, King SB et al (2022) The experience of a severe hypoglycaemic event from the perspective of people with diabetes and their caregivers: \u201cWhat am I going to do?\u201d Diabet Med 39:e14745. https:\/\/doi.org\/10.1111\/dme.14745","journal-title":"Diabet Med"},{"key":"6366_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1037\/a0037754","volume":"20","author":"G Johns","year":"2015","unstructured":"Johns G, Miraglia M (2015) The reliability, validity, and accuracy of self-reported absenteeism from work: a meta-analysis. J Occup Health Psychol 20:1\u201314. https:\/\/doi.org\/10.1037\/a0037754","journal-title":"J Occup Health Psychol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06366-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:08:23Z","timestamp":1770772103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06366-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6366"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06366-x","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors would like to thank the data nurses, the local investigators and their teams for monitoring the participants, collecting the data and completing the case reporting files. We would also like to thank R. Carette and S. Getteman (KU Leuven, Leuven, Belgium) for their help in gathering and processing data from the study. Parts of this study were presented at the 17th International Conference On Advanced Technologies & Treatments For Diabetes, 6\u20139 March 2024 in Florence, Italy and at the 60th International Conference On European Association for the Study of Diabetes, 9\u201313 September 2024 in Madrid, Spain.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"The datasets generated during and\/or analysed in the current study are available from the corresponding author upon reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This work was supported by a research grant from Tandem Diabetes Care and Dexcom.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JDM received research support from Tandem Diabetes Care and Dexcom via KU Leuven. JDM serves or has served on the speakers bureau for Dexcom; financial compensation for these activities has been received by KU Leuven. CDB reports consulting fees and honoraria for speaking for Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Insulet, Medtronic, Novo Nordisk and Roche. LVH reports consulting fees and honoraria for speaking for Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, Merck Sharp and Dohme, Novo Nordisk, Sanofi-Aventis and Roche. YT reports honoraria for speaking for Boehringer Ingelheim, Eli Lilly, Daiichi Sankyo and Bayer. KS reports consulting fees and honoraria for speaking for Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic and Merck Sharp and Dohme. GV serves, or has served, on the advisory panel for Merck Sharp and Dohme, Boehringer Ingelheim and Eli Lilly. GV reports consulting fees and honoraria for speaking for Merck Sharp and Dohme, Boehringer Ingelheim, AstraZeneca, Sanofi-Aventis, Novo Nordisk and Eli Lilly. CV reports honoraria for speaking for Eli Lilly. IMC reports honoraria for speaking for Novo Nordisk, Eli Lilly, Sanofi and Abbott. IMC serves, or has served, on the advisory panel for Novo Nordisk, Eli Lilly, Sanofi and Abbott. VP reports consulting fees and honoraria for speaking for Novo Nordisk, Sanofi and Abbott. SC received research support from Roche Diabetes Care, Novo Nordisk and Sanofi via KU Leuven. CM serves or has served on the advisory panel for Novo Nordisk, Sanofi, Merck Sharp and Dohme, Eli Lilly, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Imcyse, Insulet, Zealand Pharma, Avotres, Mannkind, Sandoz and Vertex. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics; CM serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, AstraZeneca and Novartis. Financial compensation for these activities has been received by KU Leuven. CM is president of EASD. All external support of EASD is to be found on\n                      \n                      . PG serves or has served on the advisory panel for Novo Nordisk, Sanofi-Aventis, Boehringer Ingelheim, Janssen Pharmaceuticals, Roche, Medtronic, Abbott and Bayer. Financial compensation for these activities has been received by KU Leuven. PG serves or has served on the speakers bureau for Merck Sharp and Dohme, Boehringer Ingelheim, Bayer, Medtronic, Insulet, Novo Nordisk, Abbott, Roche, VitalAire and Dexcom. Financial compensation for these activities has been received by KU Leuven. KU Leuven received for PG non-financial support for travel from Sanofi-Aventis, A. Menarini Diagnostics, Novo Nordisk, Medtronic and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"JDM designed the study, collected and analysed the data, performed statistical analyses, wrote the manuscript and made figures and tables. BK, CDB, LVH, YT, DB, KS, BL, GV, IL, CV, IMC, VP and SC collected and discussed the data and edited the manuscript. SF provided statistical advice and edited the manuscript. CM and PG designed the study, analysed and discussed the data and wrote the manuscript. All authors approved the final version to be published. JDM and PG are guarantors of this work and, as such, had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}